OmniAb Inc 2025年季度报告

☒Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 ☐Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 OMNIAB, INC. (Exact name of registrant as specified in its charter) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, oran emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth Large Accelerated FilerNon-Accelerated FilerEmerging Growth Company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of May1, 2025, the registrant had122,335,336shares of common stock outstanding. TABLE OF CONTENTS PART I. FINANCIAL INFORMATION ITEM 1. Condensed Consolidated Financial Statements (unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of OperationsCondensed Consolidated Statements of Comprehensive LossCondensed Consolidated Statements of Stockholders' EquityCondensed Consolidated Statements of Cash FlowsNotes to Condensed Consolidated Financial StatementsITEM 2. Management's Discussion and Analysis of Financial Condition and Results of OperationsITEM 3. Quantitative and Qualitative Disclosures about Market RiskITEM 4. Controls and ProceduresPART II. OTHER INFORMATIONITEM 1. Legal ProceedingsITEM 1A. Risk FactorsITEM 2. Unregistered Sales of Equity Securities and Use of ProceedsITEM 3. Defaults Upon Senior SecuritiesITEM 4. Mine Safety DisclosuresITEM 5. Other InformationITEM 6. ExhibitsSIGNATURES Part I – Financial Information OMNIAB, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited) CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Net loss (Unaudited)(in thousands, except share data) OMNIAB, INC.Notes to Condensed Consolidated Financial Statements 1. Organization and Basis of Presentation Description of Business OmniAb, Inc. (“OmniAb” or the “Company”, formerly known as Avista Public Acquisition Corp. II (“APAC”)) is a biotechnologycompany that licenses cutting-edge discovery research technology to the pharmaceutical and biotech industries and academic institutions toenable the discovery of next-generation therapeutics. The Company’s technology platform creates and screens diverse antibody repertoiresand is designed to quickly identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. At the Business Combination On November 1, 2022 (the “Closing Date”), the Company, Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Ligand”),OmniAb Operations, Inc., a Delaware corporation and wholly-owned subsidiary of Ligand (“Legacy OmniAb”, formerly known asOmniAb, Inc.), and Orwell Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of APAC (“Merger Sub”), Basis of Presentation The Company’s accompanying condensed consolidated financial statements have been prepared in accordance withgenerallyaccepted accounting principles in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to referto the authoritative U.S. GAAP as included in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates(“ASU”) of the Financial Accounting Standards Board (“FASB”). The financial information for the three months ended March31, 2025 The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly ownedsubsidiaries. All intercompany transactions and accounts within the Company have been eliminated. Liquidity and Capital Resources The Company expects to continue to incur losses as it invests in research and development activities to improve its technologyplatform, market and sell its technologies to existing and new partners, add operational, financial and management information systemsand personnel to support its operations and incur ongoing costs associated with operating as a public company. The Company’s a